
Lei Yao
Examiner (ID: 12775, Phone: (571)272-3112 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1642 |
| Total Applications | 1328 |
| Issued Applications | 662 |
| Pending Applications | 127 |
| Abandoned Applications | 552 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 13826673
[patent_doc_number] => 20190016821
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-17
[patent_title] => STABILIZED PEPTIDE FRAGMENTS FROM PROTOCADHERIN FAT1 AS CANCER BIOMARKERS
[patent_app_type] => utility
[patent_app_number] => 16/068629
[patent_app_country] => US
[patent_app_date] => 2017-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7558
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -47
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16068629
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/068629 | STABILIZED PEPTIDE FRAGMENTS FROM PROTOCADHERIN FAT1 AS CANCER BIOMARKERS | Jan 4, 2017 | Abandoned |
Array
(
[id] => 11588514
[patent_doc_number] => 20170112925
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-04-27
[patent_title] => 'METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS'
[patent_app_type] => utility
[patent_app_number] => 15/399118
[patent_app_country] => US
[patent_app_date] => 2017-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 35418
[patent_no_of_claims] => 53
[patent_no_of_ind_claims] => 30
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15399118
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/399118 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | Jan 4, 2017 | Issued |
Array
(
[id] => 13793395
[patent_doc_number] => 20190010236
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-10
[patent_title] => METHODS AND COMPOSITIONS FOR DECTIN-2 STIMULATION AND CANCER IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 16/066154
[patent_app_country] => US
[patent_app_date] => 2016-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27453
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16066154
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/066154 | METHODS AND COMPOSITIONS FOR DECTIN-2 STIMULATION AND CANCER IMMUNOTHERAPY | Dec 27, 2016 | Abandoned |
Array
(
[id] => 11589739
[patent_doc_number] => 20170114150
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-04-27
[patent_title] => 'ANTI-BRDU ANTIBODIES AND METHODS OF USE'
[patent_app_type] => utility
[patent_app_number] => 15/382329
[patent_app_country] => US
[patent_app_date] => 2016-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 23863
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15382329
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/382329 | ANTI-BRDU ANTIBODIES AND METHODS OF USE | Dec 15, 2016 | Abandoned |
Array
(
[id] => 13593345
[patent_doc_number] => 20180348221
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => Reagents and Methods for Monitoring Breast Cancer Therapy
[patent_app_type] => utility
[patent_app_number] => 15/781373
[patent_app_country] => US
[patent_app_date] => 2016-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9435
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15781373
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/781373 | Reagents and Methods for Monitoring Breast Cancer Therapy | Dec 8, 2016 | Abandoned |
Array
(
[id] => 16941089
[patent_doc_number] => 11053310
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-06
[patent_title] => Antibodies for the treatment of cancers
[patent_app_type] => utility
[patent_app_number] => 15/780334
[patent_app_country] => US
[patent_app_date] => 2016-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 19456
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15780334
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/780334 | Antibodies for the treatment of cancers | Dec 4, 2016 | Issued |
Array
(
[id] => 13729883
[patent_doc_number] => 20180369409
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-27
[patent_title] => TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN
[patent_app_type] => utility
[patent_app_number] => 15/779490
[patent_app_country] => US
[patent_app_date] => 2016-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50240
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15779490
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/779490 | Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen | Nov 28, 2016 | Issued |
Array
(
[id] => 16985506
[patent_doc_number] => 11072662
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-27
[patent_title] => Humanized anti-CLL-1 antibodies
[patent_app_type] => utility
[patent_app_number] => 15/779025
[patent_app_country] => US
[patent_app_date] => 2016-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 22296
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15779025
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/779025 | Humanized anti-CLL-1 antibodies | Nov 21, 2016 | Issued |
Array
(
[id] => 17329204
[patent_doc_number] => 11219645
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-01-11
[patent_title] => Tumor infiltrating lymphocytes for treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 15/777253
[patent_app_country] => US
[patent_app_date] => 2016-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 75
[patent_no_of_words] => 18073
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15777253
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/777253 | Tumor infiltrating lymphocytes for treatment of cancer | Nov 17, 2016 | Issued |
Array
(
[id] => 14005607
[patent_doc_number] => 10221240
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-03-05
[patent_title] => Methods for treatment of gastric cancer
[patent_app_type] => utility
[patent_app_number] => 15/345618
[patent_app_country] => US
[patent_app_date] => 2016-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 12029
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 241
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15345618
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/345618 | Methods for treatment of gastric cancer | Nov 7, 2016 | Issued |
Array
(
[id] => 12979870
[patent_doc_number] => 20170342161
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-30
[patent_title] => ANTIBODY BINDING TO CARBONIC ANHYDRASE AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/344764
[patent_app_country] => US
[patent_app_date] => 2016-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14812
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15344764
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/344764 | Antibody binding to carbonic anhydrase and use thereof | Nov 6, 2016 | Issued |
Array
(
[id] => 13533751
[patent_doc_number] => 20180318418
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-08
[patent_title] => ANTI-BARF1 MONOCLONAL ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 15/773296
[patent_app_country] => US
[patent_app_date] => 2016-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5574
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15773296
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/773296 | Anti-BARF1 monoclonal antibody | Nov 3, 2016 | Issued |
Array
(
[id] => 16563262
[patent_doc_number] => 10888609
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-01-12
[patent_title] => CD200 inhibitors and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 15/773527
[patent_app_country] => US
[patent_app_date] => 2016-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 36
[patent_no_of_words] => 28564
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15773527
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/773527 | CD200 inhibitors and methods of use thereof | Nov 1, 2016 | Issued |
Array
(
[id] => 12247356
[patent_doc_number] => 09920123
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-03-20
[patent_title] => 'Anti-PD-L1 antibodies, compositions and articles of manufacture'
[patent_app_type] => utility
[patent_app_number] => 15/335278
[patent_app_country] => US
[patent_app_date] => 2016-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 19
[patent_no_of_words] => 66198
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 142
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15335278
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/335278 | Anti-PD-L1 antibodies, compositions and articles of manufacture | Oct 25, 2016 | Issued |
Array
(
[id] => 11692345
[patent_doc_number] => 20170168061
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-06-15
[patent_title] => 'SPECIFIC BIOMARKER SET FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER'
[patent_app_type] => utility
[patent_app_number] => 15/331472
[patent_app_country] => US
[patent_app_date] => 2016-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 5372
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15331472
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/331472 | Specific biomarker set for non-invasive diagnosis of liver cancer | Oct 20, 2016 | Issued |
Array
(
[id] => 11589716
[patent_doc_number] => 20170114127
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-04-27
[patent_title] => 'VEGF-A-BINDING PROTEINS AND HER2-BINDING PROTEINS WITH ENHANCED STABILITY AGAINST AGGREGATION'
[patent_app_type] => utility
[patent_app_number] => 15/299861
[patent_app_country] => US
[patent_app_date] => 2016-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 18105
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 18
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15299861
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/299861 | VEGF-A-BINDING PROTEINS AND HER2-BINDING PROTEINS WITH ENHANCED STABILITY AGAINST AGGREGATION | Oct 20, 2016 | Abandoned |
Array
(
[id] => 11949779
[patent_doc_number] => 20170253931
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-09-07
[patent_title] => 'POST-TREATMENT BREAST CANCER PROGNOSIS'
[patent_app_type] => utility
[patent_app_number] => 15/298128
[patent_app_country] => US
[patent_app_date] => 2016-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11570
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15298128
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/298128 | Post-treatment breast cancer prognosis | Oct 18, 2016 | Issued |
Array
(
[id] => 14185373
[patent_doc_number] => 20190112391
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-18
[patent_title] => HEPARANASE-NEUTRALIZING MONOCLONAL ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 15/767355
[patent_app_country] => US
[patent_app_date] => 2016-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15802
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15767355
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/767355 | Heparanase-neutralizing monoclonal antibodies | Oct 12, 2016 | Issued |
Array
(
[id] => 13781017
[patent_doc_number] => 20190004047
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-03
[patent_title] => GDF-15 AS A DIAGNOSTIC MARKER FOR MELANOMA
[patent_app_type] => utility
[patent_app_number] => 15/765187
[patent_app_country] => US
[patent_app_date] => 2016-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27245
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15765187
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/765187 | GDF-15 AS A DIAGNOSTIC MARKER FOR MELANOMA | Sep 29, 2016 | Abandoned |
Array
(
[id] => 12565992
[patent_doc_number] => 10017572
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-07-10
[patent_title] => Anti-tigit antibodies and methods of use
[patent_app_type] => utility
[patent_app_number] => 15/274603
[patent_app_country] => US
[patent_app_date] => 2016-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 68736
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15274603
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/274603 | Anti-tigit antibodies and methods of use | Sep 22, 2016 | Issued |